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1. Introduction  
Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions 
that occur when non-radioactive boron-10 (10B) is irradiated with neutrons of the appropriate 
energy to yield high energy alpha particles (4He) and recoiling lithium-7 (7Li) nuclei. Since 
these particles have pathlengths of approximately one cell diameter, their lethality primarily is 
limited to boron containing cells. BNCT, therefore, can be regarded as both a biologically and a 
physically targeted type of radiation therapy (Fig. 1). Its success is dependent upon the 
selective delivery of sufficient amounts of 10B to cancer cells with only small amounts localized 
in the surrounding normal tissues. A wide variety of boron delivery agents have 
 
 
Fig. 1. The principle of boron neutron capture therapy (BNCT).  
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been synthesized (Hiramatsu et al. 2011, Miyata et al. 2011, Wu et al. 2007, Yang et al. 2006), 
but only two of these currently are being used in clinically. The first, which has been used 
primarily in Japan, is sodium borocaptate or BSH, and the second is a dihydroxyboryl 
derivative of phenylalanine referred to as boronophenylalanine or BPA (Barth et al. 2005). 
The latter has been used in clinical trials in Japan, Europe and the United States, primarily 
for the treatment of high grade gliomas, and more recently for recurrent tumors of the head 
and neck region (Ariyoshi et al. 2007, Haginomori et al. 2009, Kimura et al. 2009). Following 
i.v. administration of either BPA or BSH by i.v. infusion, the tumor site is irradiated with 
neutrons, the source of which is a nuclear reactor.  
Recently, BNCT studies carried out by us at Osaka Medical College (OMC) and Kyoto 
University Research Reactor Institute (KURRI), in which BPA and BSH were administered 
in combination (Kawabata et al. 2003, Miyatake et al. 2005, Miyatake et al. 2009) for the 
patients with recurrent tumor after irradiation, or BNCT followed by an X-ray boost showed 
favorable responses in patients with newly-diagnosed glioblastoma (GB) and especially 
those in high risk groups (Kawabata et al. 2009a). 
2. Clinical studies of our modified boron neutron capture therapy  
Since the 1950s, BNCT has been used to treat malignant gliomas, although the results have 
not been satisfactory. We modified the therapy in several ways to resolve problems 
previously existing, and applied this modified BNCT to malignant gliomas beginning in 
2002 by using KURRI (Kawabata et al. 2003). First, we utilized an epithermal rather than a 
thermal beam to improve the distribution of thermal neutrons in deep sites. Second, we 
used both of the boron compounds that are currently available worldwide for BNCT: 
sodium borocaptate (BSH) and boronophenylalanine (BPA). These compounds reach 
different subpopulations of tumor cells and accumulate in them in a different fashion. 
2.1 Survival benefit from modified boron neutron capture therapy in combination with 
external beam fractionated X-ray treatment 
We evaluate the clinical results of a form of tumor selective particle radiation, BNCT in 
combination with external beam fractionated X-ray treatment (XRT) for newly-diagnosed 
GB patients. Between 2002 and 2006, we treated 21 patients of newly-diagnosed GB with 
BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 
were treated with only BNCT (protocol 1), and the last 11 were treated with BNCT followed 
by fractionated XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor 
recurrence. No chemotherapy was applied until tumor progression was observed. 
2.1.1 Methods and the study design of our modified BNCT with XRT 
As mentioned previously, we modified the protocol of BNCT as follows: First, we started 
using epithermal neutrons instead of thermal neutrons to obtain good penetration for deep-
seated lesions. Second, we simultaneously used 2 different boron compounds (BSH and 
BPA) with different accumulation mechanisms to the tumor cells (Ono et al. 1999, Yokoyama 
et al. 2006). Third, we utilized a dose simulation work station, the Simulation Environments 
for Radiotherapy Applications (SERA; Idaho National Laboratory, Idaho Falls, ID) or  the 
JAERI computational dosimetry system (JCDS). Fourth, 18F-labeled BPA positron emission 
tomography (18F-BPA-PET) (Fig.2) was applied for the estimation of the boron compound 
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accumulation prior to neutron irradiation (Imahori et al. 1998). Fifth, we filled the tumor 
removed cavity with air to obtain enough neutron flux, especially for the bottom of deep-
seated tumors (Sakurai et al. 2006). Sixth, we developed a central shielding method with a 
lithium plate at the center of the irradiation field to obtain uniform neutron distribution and 
increase the neutron flux relativey at the periphery in the radiation field (Ono 2006, Ono et 
al. 2000). With these modifications, even patients with deep-seated tumors can be treated by 
BNCT without craniotomy with a short hospital stay. In the present study, the revised 
protocol was used as a new protocol as follows. 
 
 
Fig. 2. 18F labeled BPA positron emmision tomography (18F - BPA PET) has been applied for 
the estimation of the boron compound accumulation prior to BNCT. The tracer is fluororide 
labelled boron compound. This PET ensures the effectiveness of BNCT. 18F-BPA 
accumulates well and distributes precisely in the tumor lesion and the infiltrating tumor 
zone. 
Twelve hours before the neutron irradiation, the patients were administered 100mg/kg of 
BSH intravenously for one hour. 700mg/kg of BPA was infused continuously to the patients 
for 6 hours before the irradiation, and they were positioned for neutron irradiation in the 
reactor (KURRI or JRR-4 (Japan Atomic Energy Agency Research Reactor 4)). Just after 
termination of continuous BPA infusion for 6hrs, neutrons were irradiated. We used the 
dose-planning workstation to calculate the radiation dose for tumors from the 18F-BPA-PET 
data and blood 10B concentrations obtained every 2 hours after BSH administration. We 
used an epithermal neutron beam. Following this, a 2 Gy daily fraction of XRT was applied, 
for a total of 20 to 30Gy. The total dose of XRT was decided based on the BNCT dose for the 
normal brain. In Protocol 1, we aimed to apply more than 30 gray-equivalent (Gy-Eq) for 
gross tumor volume (GTV) and less than 12 Gy-Eq for normal brain, as BNCT. In Protocol 2, 
we aimed to apply more than 40 Gy-Eq for GTV and less than 15 Gy-Eq for normal brain. 
No chemotherapy was applied for any of the patients until the tumor progression was 
confirmed histologically or by 18F-BPA-PET (Miyashita et al. 2008). 
Survival time from histologically diagnosed as GB was compared with the survival time for 
the institutional historical controls who were treated by surgical removal followed by XRT 
and chemotherapy (mainly nitrosourea) from 1990 to 2006 in OMC. In this historical control 
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group, all cases were operated on to aim for the maximum tumor removal, the same as for 
the cases of the BNCT group. These Kaplan–Meier curves were calculated and the Log-rank 
test was used for statistical analysis. For the 21 patients who received BNCT, survival time 
was also compared with the corresponding recursive partitioning analysis (RPA) subclasses 
by the Radiation Therapy Oncology Group (RTOG) (Curran et al. 1993), as the international 
historical control, and European Organisation for Research and Treatment of Cancer -
National Cancer Institute of Canada (EORTC-NCIC) trial (Stupp et al. 2009). 
2.1.2 Results from our past study 
Patients treated with BNCT (n=21) had a median ST of 15.6 months (95% confidence interval 
(CI): 12.2-23.9) after diagnosis (Fig. 3). Here the date of diagnosis is the initial debulking 
surgery date. This was significantly longer than the median survival time (MST) for the 
historical controls at our institute who were treated with surgical removal followed by XRT 
and chemotherapy (n=27, MST was 10.3 months (95% CI: 7.4-13.2), log-rank test p = 0.0035). 
The survival time from the date of diagnosis was calculated using the Kaplan-Meier 
method. The MST of the protocol 2 was 23.5 months (95% CI: 10.2 - undetermined) after 
diagnosis (n=11), and that of the protocol 1 patients (n=10) was 14.1 months (95% CI: 9.9-
18.5), although the difference was not statistically significant (Fig. 4).  
 
 
Fig. 3. Cumulative survival data for all newly diagnosed glioblastoma (WHO grade 4, 
n=21). Blue line is our recent historical control treated by external beam X-ray irradiation. 
The median survival time (ST) of boron neutron capture therapy (BNCT) group (red line) 
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The RPA class distribution of 21 patients treated with BNCT at the initial diagnosis was as 
follows: Class III = 6 (29%); Class IV = 6 (29%); Class V = 8 (38%); Class VI = 1 (5%). The 
MSTs of the patients in classes III, IV, V, and VI were 23.5, 16.9, 13.2, and 9.8 months, 
respectively (Table 1). In historical control, the RPA class distribution was as follows: Class 
III = 3 (11%); Class IV = 14 (52%); Class V = 8 (30%); Class VI = 2 (7%). The distributions of 
each RPA class in BNCT group and institutional historical control group are a little bit 
different. We compare the survival of both groups in low risk RPA (class III and IV) and in 
high risk RPA (class V and IV) separately. The MST of BNCT group in low risk group was 
18.5 months (n=12, 95% CI: 13.7-36.1) and that of historical control was 13.0 months (n=17, 
95% CI: 8.6-18.0). There is statistical significance in log-rank test (p=0.028). The MST of 
BNCT group in high risk group was 12.2 months (n=9, 95% CI: 9.8-undetermined) and that 
of historical control was 7.4 months (n=10, 95% CI: 2.7-10.3). There is also statistical 
significance in log-rank test (p=0.0083). Therefore, it can be concluded that BNCT group 
shows the long survival in comparison with historical control not mainly by the difference 
of distribution of each RPA class in both groups. Our BNCT results for survival among the 
newly-diagnosed GB cases were favorable in comparison with those obtained from the 
corresponding RTOG - RPA subclasses. 
 
 
Fig. 4. Cumulative survival data for all newly diagnosed glioblastoma (protocol 1 and 2). 
External beam X-ray irradiation boost after boron neutron capture therapy (BNCT) (protocol 
2, red line) was indicated for later 11 cases. This improve the median survival time as 23.5 
months (vs 14.1 months for BNCT only (protocol 1, dotted red line)).  
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XRT  XRT TMZ/XRT  XRT BNCT 
III 17.9  14.8 18.7  13.4 23.5 
IV 11.1  13.3 16.3  12.8 16.9 
V 8.9  9.1 10.7  7.4 13.2 
VI 4.6  Not reported  3.6 9.8 
*Median survival time (months). RTOG: radiation therapy oncology group, EORTC: 
european organisation for research and treatment of cancer, NCIC: National Cancer 
Institute of Canada Clinical Trials, RPA: recursive partitioning analysis, XRT: X-ray 
radiation therapy, TMZ: Temozolomide, BNCT: boron neutron capture therapy. 
Table 1. Comparison of survival data among RPA class in the RTOG database, EORTC-
NCIC (XRT/TMZ) trial, and in our cases treated with BNCT. 
2.2 Representative case treated by modified boron neutron capture therapy 
combination with fractionated X-ray irradiation 
A 63-year old female had a left parietal tumor removed partially in a hospital in November 
2004. The histopathological diagnosis was GB. She was introduced to our hospital for BNCT 
for the remaining lesion. While she waited for the BNCT, rapid growth of the tumor caused 
aggravations of right hemiparesis, total aphasia and consciousness disturbance, all of which 
caused us to remove the tumor again in our hospital prior to BNCT. The tumor was gross 
totally removed, and the patient received BNCT with air instillation in tumor removed 
cavity, followed by XRT. At the time of BNCT, the workstation calculates two different 
estimated doses, one is for the tumor and the other is for the normal brain (Fig. 5). 
Dose calculation shows estimated gray-equivalent (Gy-Eq) isodose lines from BNCT. This is 
mainly based on the decay of the irradiated neutron, boron concentration and biological 
effectiveness of each tissue. The deepest part of the tumor was 7.5 cm from the scalp in this 
case. The irradiated minimum tumor dose by BNCT was improved by the air-instilation 
(star in the Fig. 5) methods from 18.9 Gy-Eq (without air) to 26.9 Gy-Eq (with air). The 
maximum irradiated point of the normal brain was 2 cm from the scalp and was 12.7 Gy-Eq 
and scalp surface was 9.0 Gy-Eq. An additional 20 Gy was applied by XRT (daily fraction of 
2 Gy x 10 days) aimed for the deep part of the mass but included surface of the tumor and 
the normal brain. 
No tumor recurrence on MRI and no neurological deficit were seen for 13 months after 
BNCT (Fig. 6). BNCT followed by fractionated XRT could control the tumor for 12 months 
(Fig. 6B). However, 14 months after BNCT, the patient suffered from right hemiparesis and 
MRI revealed a Gd-enhanced lesion from the surface area of the tumor removed cavity 
which was irradiated by BNCT with enough dose and also included into the boost XRT (Fig. 
6C). Radiation necrosis was suspected as the pathological condition based on L/N ratio in 
BPA-PET, but we could not neglect the possibility of a recurrence of the GB. We performed 
a re-craniotomy to remove this lesion. The pathological diagnosis was radiation necrosis; no 
apparent tumor cells were found by pathologists. After the surgery, the right hemiparesis 
was improved, while no tumor progression was observed on MRI in the follow-up for more 
than 5 years (Fig. 6D). The patient received best medical treatment (anti-coagulants and 
vitamin E) for a year to prevent a further radiation necrosis. 
www.intechopen.com
 




Fig. 5. Dose planning of neutron capture therapy for the tumor (upper) and for the normal 
brain (lower). (Gy-Eq: gray equivalent, star: air instillation to the tumor removed cavity) 
 
 
Fig. 6. Serial MRI images (T1-weighted with Gd enhancement) of the patient treated by boron 
neutron capture therapy combined with fractionated external beam X-ray irradiation. (A: prior 
to surgical removal and BNCT, B: 12 months, C: 14 months and D: 5 years after BNCT).  
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2.3 Phase II clinical study of boron neutron capture therapy combined with X-ray 
radiotherapy / Temozolomide in patients with newly diagnosed glioblastoma 
multiforme 
Results of our clinical study showed the efficacy of combination therapy with external beam 
XRT and BNCT. For our future study, we planned the Multi-centric Phase II clinical study 
named “Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating 
Patients with Newly Diagnosed Glioblastoma Multiforme” in Japan (OSAKA-TRIBRAIN0902, 
NCT00974987). The major differences of our protocol from the other past BNCT studies 
were simultaneous use of both BSH and BPA, and combination with XRT.  
2.3.1 Back ground of our recently up-dated protocol using BNCT 
Prior to design of new version of the protocol for multi-centric study, we analyzed our 
previous clinical results of all the patients with malignant glioma treated by BNCT. Main 
part of the retrospective analysis was as follows. 1. Efficacy of additional fractionated X-ray 
irradiation, 2. Administration of the boron compouns, 3. Toxicity of our previous study. The 
median ST of the patients treated with BNCT followed by XRT boost was 23.5 months (95% 
CI: 10. 2 – undetermined, HR (vs control) = 0.32) after diagnosis (n = 11), and that of the 
patients treated with BNCT only (n = 10) was 14.1 months (95% CI: 9.9–18.5), although the 
difference was not statistically significant among these two groups. 
In our previous study for all of the patients with malignant brain tumor included several 
doses of boron compounds especially for BPA, 250, 500, 700mg/kg body weight. Blood 
boron concentration was increased by escalation of the BPA dose. The continuous infusion 
with reduced BPA dose during irradiation (400mg/kg for 2h + 100mg/kg for 1h, previously 
used for head and neck cancer in KURRI) was also used and this was useful for dose 
estimation of BNCT because the blood boron concentration similar as 700mg BPA/kg was 
kept during irradiation whereas a decline of the blood level was remarkable when we 
terminated BPA just before neutron irradiation. Adverse events were assessed by common 
terminology criteria for adverse events (CTCAE) v3.0. Grade 3/4 blood/bone marrow 
toxicity (hemoglobin, leukocytes, neutrophils, and platelets) were 11% in 250mg/kg, 17% in 
500mg/kg, and 28% in 700mg/kg. Other Grade 3/4 adverse events (seizure, AST, ALT, 
amylase, creatinine) were 64% in 250mg/kg, 25% in 500mg/kg, and 73% in 700mg/kg. All 
of these adverse events were reversible and transient. Radiation induced edema and/or 
necrosis occurred mainly in the area that was available for high-dose irradiation by BNCT 
nearly the surface of the brain of the patients treated with BNCT+XRT. Based on this 
retrospective analysis, the Multi-centric Phase II clinical study was planned and now on-
going. 
2.3.2 On-going protocol using BNCT for the newly diagnosed glioblastoma 
Based on our former BNCT clinical experience, we included the following points in a new 
protocol using the two boron compounds, BSH and BPA, in combination (Ono et al. 1999, 
Yokoyama et al. 2006). The schedule of the administration of boron compounds is settled as 
follows; 13 hours before the neutron irradiation, 100 mg/kg of BSH will be intravenously 
infused for one hour, and 500 mg/kg of BPA will be infused continuously 200 mg/kg/h for 
2 hours before the irradiation and reduced for 100 mg/kg/h during irradiation to the 
patients. During continuous BPA infusion of reduced dose as 100 mg/kg, neutrons 
irradiation is performed. Protocol treatments consist of BNCT, additional 24Gy XRT and 
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chemotherapy with TMZ. Prescription dose by BNCT is regulated as not to be more than 
13Gy-Eq for normal brain. Additional XRT is given with 3 gradient such as 8, 16, 24Gy from 
the surface of scalp to the bottom of tumor infiltrated zone (Fig. 7). Chemotherapy with 
TMZ is applied concomitantly during XRT treatments and adjuvant chemotherapy with the 









Fig. 7. Illustrated image of the protocol combined with boron neutron capture therapy 
(BNCT) and 3 gradient fractionated X-ray irradiation (XRT). Gy: gray, fr: fraction. 
Based on our previous clinical study, the Hazard ratio of BNCT vs. XRT was simulated as 
0.4, so the total estimated number of the patients who should be included in our new study 
become 45 totally. Primary end point is overall survival and these patients will be followed 
up for 2 years after the last patient treatment. The most important point in our protocol is 
diagnosis and treatment of radiation effects such as swelling, radiation induced edema, 
transient expansion of the tumor, pseudo- progression / response, and radiation necrosis. 
18F-BPA-PET study is included for the diagnosis of these pathologies. 
www.intechopen.com
 




Fig. 8. Treatment protocol of BNCT combination with EBRT/TMZ for Newly diagnosed 
Malignant Glioma 
3. Conclusion 
Glioblastoma is currently not curable and the prognosis of it is very poor. A world-wide 
standard care of newly-diagnosed GB is postoperative XRT with concomitant and adjuvant 
chemotherapy with new alkylating agent TMZ(Stupp et al. 2005). This standard treatment 
for newly diagnosed GB prolonged the median ST of patients from 12.1 months to 14.6 
months in comparison with XRT alone, which is still pessimistic clinical result of this 
disease. Therefore an alternative promising treatment should be developed for the 
improvement of the prognosis of newly diagnosed GB. Several recent clinical studies on the 
treatment of patients with GB by means of BNCT have reported encouraging results. 
Careful analysis of survival data from a study, carried out in Sweden (Skold et al.) in which 
BPA was administered at a higher dose over a longer period of time (Skold et al.), suggested 
that a subset of patients had survival times that were at least as good as those obtained with 
conventional therapy consisting of X-irradiation in combination with TMZ (Stupp et al. 
2005). 
On the other hand, BNCT is tumor-selective particle radiation. Tumor-seeking boron 
compounds boronophenylalanine (BPA) and sodium borocapate (BSH) can be delivered 
selectively in GB tissue with high contrast of accumulation in comparison with normal brain 
tissue. This tumor selective accumulation of boron compounds is followed by neutron 
irradiation, which produced high linear energy transfer particles (alpha particle and re-
coiled Li nucleus). Thereafter these particles can destroy tumor cells selectively with high 
efficiency (Barth et al. 2005). The principal investigator of this clinical trial published the 
excellent survival data of 21 cases of newly diagnosed GB treated by BNCT with the MST of 
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15.6 months without TMZ. Moreover additional 20 to 30Gy XRT prolonged the MST up to 
23.5 months in 11 cases without TMZ (Kawabata et al. 2009b). These strategies were also 
confirmed by pre-clinical bench works (Barth et al. 2004). These are the background of our 
on-going clinical trial. Thereafter in this trial, the protocol is composed of BNCT, followed 
by 24Gy XRT with concomitant and adjuvant chemotherapy with TMZ for newly diagnosed 
GB patients. 
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